Key Highlights

  • Shares are trading 27.46% higher at $0.61 on Wednesday, October 28, 2026, from a $0.4821 close on October 26.
  • The lender forbearance period was extended on October 22 to 11:59 p.m. Eastern time on November 1, 2026.
  • Cash and equivalents were $55.0 million at June 30, 2026, with $10.1 million more in investments.
  • Second-quarter revenue fell to $33.4 million from $37.9 million, with a net loss of $67.0 million.
  • Short interest was 7,266,973 shares for the settlement date of October 15, 2026, or 4.84 days to cover.

Karyopharm Penny Stock: Why Is a Distressed Drugmaker Among the Most Active Names Today?

Karyopharm (NASDAQ:KPTI) shares are trading 27.46% higher at $0.61 on Wednesday, October 28, 2026, which puts the stock among the most heavily traded penny stocks on the day. The shares closed at $0.4821 on Monday, October 26, after a 6.84% decline that day, so today's rise follows a sharp slide. No dated company release accompanied the move.

Karyopharm is a commercial-stage drugmaker based in Newton, Massachusetts, and its main marketed product is the cancer medicine XPOVIO. With about 22.68 million shares outstanding, the equity is valued at roughly $13.8 million at $0.61 (calculated), against a 52-week range of $0.31 to $10.99.

Karyopharm Forbearance Agreement: How Long Do Noteholders Hold Off?

On September 10, 2026, Karyopharm and its subsidiary guarantors signed a Forbearance Agreement and waiver to its indentures. An 8-K reporting events of October 13 moved the end of the forbearance period from October 15 to October 22, and a second 8-K dated October 22 pushed it to 11:59 p.m. Eastern time on November 1, 2026.

Both filings give only the dates, not the terms being negotiated.

At June 30, 2026, debt carried at about $249.9 million included $98.7 million of 2029 convertible notes, $25.9 million of 2028 convertible notes and a $125.4 million term loan due May 2028.

Karyopharm Liquidity: Can $65 Million Cover $69.5 Million in Scheduled Payments?

Cash and cash equivalents were $55.0 million at June 30, 2026, and with $10.1 million of investments the total was $65.1 million. The quarterly report lists scheduled debt payments of $69.5 million for the twelve months through June 30, 2027, and said management concluded there is substantial doubt about the company's ability to continue as a going concern.

Second-quarter revenue was $33.4 million, down from $37.9 million a year earlier, with XPOVIO net product revenue of $30.8 million. The net loss was $67.0 million for the quarter and $89.4 million for the six months ended June 30.

A Phase 3 endometrial cancer study, XPORT-EC-042, missed its primary endpoint, and the shares fell about 69% on that outcome. A myelofibrosis application for XPOVIO plus ruxolitinib was submitted on August 31, 2026.

Karyopharm Short Interest: What Could 32% of Shares Sold Short Mean?

Short-interest data for the settlement date of October 15, 2026 shows 7,266,973 shares sold short, up 1,210,811 from the prior reading. That equals about 32% of shares outstanding (calculated, since float is not reported) and 4.84 days of average volume to cover.

A large short position can magnify moves either way, since buying to close positions can add to a rise.

What to Watch Next: November 1 Forbearance Deadline and Third-Quarter Results

The immediate date is 11:59 p.m. Eastern time on November 1, 2026, when the forbearance period ends unless extended again or terminated earlier. Third-quarter results are estimated for around November 6, updating cash, debt and the going-concern language.